H • LAC Westbury
... Hydrocodone is a semisynthetic opioid antitussive and analgesic with multiple actions qualitatively similar to those of codeine . The precise mechanism of action of hydrocodone and other opiates is not known ; however, hydrocodone is believed to act directly on the cough center . In excessive doses ...
... Hydrocodone is a semisynthetic opioid antitussive and analgesic with multiple actions qualitatively similar to those of codeine . The precise mechanism of action of hydrocodone and other opiates is not known ; however, hydrocodone is believed to act directly on the cough center . In excessive doses ...
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS)
... The methanolic extract of Coccinia grandis leaf and fruit was administered at doses to normal and diabetic rats. The methanolic extract at 400 mg/kg body weight dose level exhibited significant hypoglycemic activity (P < 0.01 and P < 0.001). Phytochemical screening of methanolic extract revealed the ...
... The methanolic extract of Coccinia grandis leaf and fruit was administered at doses to normal and diabetic rats. The methanolic extract at 400 mg/kg body weight dose level exhibited significant hypoglycemic activity (P < 0.01 and P < 0.001). Phytochemical screening of methanolic extract revealed the ...
DISCLAIMER STATEMENT
... The purpose of this background document is to provide summary information on issues related to clinical trial designs and endpoints for community-acquired bacterial pneumonia (CABP) and describe outstanding issues where the FDA’s Anti-Infective Drugs Advisory Committee (AIDAC) can provide additional ...
... The purpose of this background document is to provide summary information on issues related to clinical trial designs and endpoints for community-acquired bacterial pneumonia (CABP) and describe outstanding issues where the FDA’s Anti-Infective Drugs Advisory Committee (AIDAC) can provide additional ...
View PDF - Open Access Journals
... included nausea (12 patients, 54.5%), fatigue, leukopenia, and neutropenia (each in nine patients, 40.9%). The most commonly reported grade ≥ 3 treatment-emergent adverse events were leukopenia and neutropenia (each in seven patients, 31.8%). Conclusions: Coadministration of ramucirumab had no effec ...
... included nausea (12 patients, 54.5%), fatigue, leukopenia, and neutropenia (each in nine patients, 40.9%). The most commonly reported grade ≥ 3 treatment-emergent adverse events were leukopenia and neutropenia (each in seven patients, 31.8%). Conclusions: Coadministration of ramucirumab had no effec ...
PDF - Romanian Journal of Anaesthesia and Intensive Care
... gesic [18]. Opioid switch requires a clearer understanding of the genetic factors contributing to the individual response to opioids in order to predict the outcome of opioid rotation in different individuals. The µ-opioid receptor gene encoded by the genetic locus OPRM1 is the primary binding site ...
... gesic [18]. Opioid switch requires a clearer understanding of the genetic factors contributing to the individual response to opioids in order to predict the outcome of opioid rotation in different individuals. The µ-opioid receptor gene encoded by the genetic locus OPRM1 is the primary binding site ...
A Practical Approach to the Treatment of Low
... since many mild cases are likely to go unreported. In a double-blind study of children taking ibuprofen (n = 76) or paracetamol (n = 74) for up to 3 days, there was only one GI event (diarrhea) reported as possibly related to treatment, and this occurred in the ibuprofen group [36]. Potentially, GI ...
... since many mild cases are likely to go unreported. In a double-blind study of children taking ibuprofen (n = 76) or paracetamol (n = 74) for up to 3 days, there was only one GI event (diarrhea) reported as possibly related to treatment, and this occurred in the ibuprofen group [36]. Potentially, GI ...
A Review of the Development of Calcium Pterins and (250:1 Mol:Mol
... nudes, to compare the antitumor activity of this suspension to pterin alone (pterin control), and to test the effect of CaPterin mega-dosing at 100 mg/(kg day). The four treatment groups were: CaPterin (7 mg/ (kg day); pterin (21 mg/(kg day)); CaPterin (21 mg/(kg day)); and sterile water control. In ...
... nudes, to compare the antitumor activity of this suspension to pterin alone (pterin control), and to test the effect of CaPterin mega-dosing at 100 mg/(kg day). The four treatment groups were: CaPterin (7 mg/ (kg day); pterin (21 mg/(kg day)); CaPterin (21 mg/(kg day)); and sterile water control. In ...
(Antiviral) Drugs
... agreed upon priority groups. With the expansion of the stockpile to 55 million doses, the strategy has been revised and is described below. Early Treatment (i.e., treatment within 48 hours of symptom onset) The National Antiviral Stockpile should be used at the time of a pandemic for early treatment ...
... agreed upon priority groups. With the expansion of the stockpile to 55 million doses, the strategy has been revised and is described below. Early Treatment (i.e., treatment within 48 hours of symptom onset) The National Antiviral Stockpile should be used at the time of a pandemic for early treatment ...
medicines control council biostudies
... be applied to comparative bioavailability studies evaluating different formulations used during the development of a new medicinal product containing a new chemical entity and to comparative bioavailability studies included in extension applications that are not based exclusively on bioequivalence d ...
... be applied to comparative bioavailability studies evaluating different formulations used during the development of a new medicinal product containing a new chemical entity and to comparative bioavailability studies included in extension applications that are not based exclusively on bioequivalence d ...
General - EmergencyPedia
... 11. The bioavaliability of a drug – defined as fraction of unchanged drug reaching systemic circulation after any route of administration. a) ...
... 11. The bioavaliability of a drug – defined as fraction of unchanged drug reaching systemic circulation after any route of administration. a) ...
New Pharmacotherapies for Type 2 Diabetes Learning Objectives
... Assumes no contraindications to metformin use. ACCE = American College of Clinical Endocrinologists; ACE = American College of Endocrinology; ACP = American College of Physicians; ADA = American Diabetes Association; BMI = body mass index; DPP-4 = dipeptidyl peptidase-4; EASD = European Association ...
... Assumes no contraindications to metformin use. ACCE = American College of Clinical Endocrinologists; ACE = American College of Endocrinology; ACP = American College of Physicians; ADA = American Diabetes Association; BMI = body mass index; DPP-4 = dipeptidyl peptidase-4; EASD = European Association ...
Enzymes
... structure (e.g. a physicochemical property) to a physical property or to a biological effect (e.g. a toxicological endpoint) -similar structures –similar effects but uses parameters to describe the potency -parameters – anything (related to drug action) that can be represented by a numerical values ...
... structure (e.g. a physicochemical property) to a physical property or to a biological effect (e.g. a toxicological endpoint) -similar structures –similar effects but uses parameters to describe the potency -parameters – anything (related to drug action) that can be represented by a numerical values ...
Duration of Dual Antiplatelet Therapy after Coronary Stent Placement
... f) Dosing: 81 mg -325 mg 3. Adverse effects9 a) Low incidence of bleeding - 2% b) Gastrointestinal ulcer - 6-30% B. P2Y12 Platelet inhibitors 1. Block the P2Y12 component of the ADP receptors on the platelet surface which prevents activation of the GPIIb/IIIa receptor complex and preventing platelet ...
... f) Dosing: 81 mg -325 mg 3. Adverse effects9 a) Low incidence of bleeding - 2% b) Gastrointestinal ulcer - 6-30% B. P2Y12 Platelet inhibitors 1. Block the P2Y12 component of the ADP receptors on the platelet surface which prevents activation of the GPIIb/IIIa receptor complex and preventing platelet ...
Rodent motor and neuropsychological behaviour measured
... cage activity monitoring, we quantified changes in activity levels induced by two stimulants, namely cocaine (30.0 mg/kg, i.p., in mice; 20.0 mg/kg, i.p., in rats) and amphetamine (20.0 mg/kg, i.p., in mice), and one sedative compound, the nociceptin/orphanin FQ (NOP) receptor agonist SR14150 (10 mg/ ...
... cage activity monitoring, we quantified changes in activity levels induced by two stimulants, namely cocaine (30.0 mg/kg, i.p., in mice; 20.0 mg/kg, i.p., in rats) and amphetamine (20.0 mg/kg, i.p., in mice), and one sedative compound, the nociceptin/orphanin FQ (NOP) receptor agonist SR14150 (10 mg/ ...
"Is BPA Safe?" with a clear answer - "Yes."
... substance with no known biological activity. Any trace amount of BPA that remains is converted in the liver to the same inactive substance before entering the bloodstream. ...
... substance with no known biological activity. Any trace amount of BPA that remains is converted in the liver to the same inactive substance before entering the bloodstream. ...
The impact of pistachio intake alone or in combination with high
... protective effect may in part be explained by the favorable impact of nuts on serum lipids (Griel and Kris-Etherton, 2006), oxidative stress (Jenkins et al., 2002) and markers of inflammation (Jiang et al., 2006; Ros, 2009). However, owing to their low available carbohydrate content and favorable fa ...
... protective effect may in part be explained by the favorable impact of nuts on serum lipids (Griel and Kris-Etherton, 2006), oxidative stress (Jenkins et al., 2002) and markers of inflammation (Jiang et al., 2006; Ros, 2009). However, owing to their low available carbohydrate content and favorable fa ...
Relationship between the Serotonergic Activity and Reinforcing
... Vanover et al., 1992; Howell and Byrd, 1995). Among amphetamine-like drugs that are not as selective for 5-HT activity, Ritz and Kuhar (1989) reported a negative correlation between potency as a reinforcer and binding affinity at the 5-HT transporter (SERT). The depletion of 5-HT by medial forebrain ...
... Vanover et al., 1992; Howell and Byrd, 1995). Among amphetamine-like drugs that are not as selective for 5-HT activity, Ritz and Kuhar (1989) reported a negative correlation between potency as a reinforcer and binding affinity at the 5-HT transporter (SERT). The depletion of 5-HT by medial forebrain ...
Antimicrobial activities of tosufloxacin against Streptococcus
... quinolones used for respiratory infections. This is a very important factor for selecting a drug. The incidence of PRSP/PISP among S. pneumoniae increased from 50.9% in the second survey to 59.6% in the third survey, indicating the serious impact of these resistant strains on the clinical use of cep ...
... quinolones used for respiratory infections. This is a very important factor for selecting a drug. The incidence of PRSP/PISP among S. pneumoniae increased from 50.9% in the second survey to 59.6% in the third survey, indicating the serious impact of these resistant strains on the clinical use of cep ...
Meta-Analysis of Combined Therapy with Angiotensin Receptor
... Background: There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure. Methodology/Principal Findings: Two independent reviewers ...
... Background: There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure. Methodology/Principal Findings: Two independent reviewers ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
... Pregnancy: There is very limited experience with buprenorphine/naloxone in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in th ...
... Pregnancy: There is very limited experience with buprenorphine/naloxone in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in th ...
Effects of nitrous oxide on diazepam sedation of young children
... injection, and rubber damapplication. In addition, by the time of the second segment, children whohad cried from the beginning often became tired and, consequently, cried less. 240American Academy of PediatricDentistry ...
... injection, and rubber damapplication. In addition, by the time of the second segment, children whohad cried from the beginning often became tired and, consequently, cried less. 240American Academy of PediatricDentistry ...
NCIC CTG Consent - BC Cancer Agency
... You will be told which treatment you are to get. or This is a double-blind study, which means that neither you nor your doctor will know if you are receivingagent or placebo. Your experimental treatment will be identified if medically necessary. Requests to unblind your experimental treatment for yo ...
... You will be told which treatment you are to get. or This is a double-blind study, which means that neither you nor your doctor will know if you are receivingagent or placebo. Your experimental treatment will be identified if medically necessary. Requests to unblind your experimental treatment for yo ...
2048998_Open_OCTREOTIDE ACETATE INJECTION SAG US.cdr
... suppression of growth hormones. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine) should therefore be used with caution. Drug Laboratory Test Interactions No known interfere ...
... suppression of growth hormones. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine) should therefore be used with caution. Drug Laboratory Test Interactions No known interfere ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.